RetinalGenix Technologies Inc. — Cyborg Score 6/10
Solid
Precision medicine diagnostics for retinal and systemic disease detection
Strategic Profile
By integrating genetic screening, advanced imaging, and therapeutic development, RetinalGenix is positioned to become a leader in precision medicine. In February 2025, the company achieved an important milestone by successfully starting imaging patients with its first prototype device using both near-infrared and green modes. In October 2025, RetinalGenix announced a strategic partnership with RGEN Inc., a leader in genetic research and innovation, to deliver advancements in the early detection and risk prediction of neurodegenerative, systemic, and retinal diseases.
Cyborg Score Rationale
RetinalGenix demonstrates solid fundamentals with innovative dual-platform technology (imaging + pharmacogenetic mapping), meaningful clinical progress (prototype testing in February 2025), strategic partnerships (RGEN collaboration in October 2025), and recent patent approvals (September 2025). However, as a developmental-stage OTC company with no reported trailing revenue as of June 2025, limited financial transparency, and substantial regulatory/commercialization risks ahead, execution remains critical before valuation inflection.
Top Insights
Patent momentum: In September 2025, received approval for U.S. Patent No. 2024/0099581 covering home/remote monitoring and physician alert systems with real-time disease detection capabilities.
Clinical prototype advancement: Began patient imaging with first-generation device in February 2025 using dual near-infrared and green imaging modes, with second prototype and design-for-manufacturing underway.
Strategic collaboration: October 2025 partnership with RGEN Inc. integrates clinical-grade DNA genotyping with retinal imaging to accelerate predictive models for AMD, glaucoma, diabetic retinopathy, and neurodegenerative diseases.
Wide deployment vision: Targets multiple distribution channels including pharmacies, malls, general practices, specialty offices, hospitals, urgent care, and nursing homes once final prototype is completed.
Named Competitors
Optos — Wide-field retinal imaging and ophthalmic diagnostic devices
Zeiss Ophthalmology — Advanced optical and imaging solutions for eye care
Heidelberg Engineering Diagnostics — High-resolution retinal imaging and diagnostic instruments
LabCorp Genetics — Genetic and genomic testing services
Recent Developments
(September 2025) Patent portfolio advances for home and remote monitoring covering peripheral retina mapping and beta-amyloid biomarkers linked to Alzheimer's disease.
(October 2025) Strategic collaboration announced with RGEN Inc. to integrate advanced retinal imaging with clinical-grade DNA genotyping for early detection of neurodegenerative and systemic diseases.
(February 2025) Achieved important milestone with successful patient imaging using first prototype device in both near-infrared and green modes; second prototype design and manufacturing phase initiated.
Open the full interactive RetinalGenix Technologies Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.